NZ307089A - Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicaments - Google Patents
Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicamentsInfo
- Publication number
- NZ307089A NZ307089A NZ307089A NZ30708996A NZ307089A NZ 307089 A NZ307089 A NZ 307089A NZ 307089 A NZ307089 A NZ 307089A NZ 30708996 A NZ30708996 A NZ 30708996A NZ 307089 A NZ307089 A NZ 307089A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- thioalkyl
- formula
- medicaments
- substituted pyrimidine
- Prior art date
Links
- -1 alkylether compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43670895A | 1995-05-08 | 1995-05-08 | |
| PCT/US1996/006119 WO1996035678A1 (en) | 1995-05-08 | 1996-05-03 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ307089A true NZ307089A (en) | 1999-07-29 |
Family
ID=23733510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ307089A NZ307089A (en) | 1995-05-08 | 1996-05-03 | Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicaments |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6043248A (enExample) |
| EP (2) | EP1449835A3 (enExample) |
| JP (1) | JPH11507017A (enExample) |
| KR (1) | KR100445498B1 (enExample) |
| CN (2) | CN1152022C (enExample) |
| AT (1) | ATE275550T1 (enExample) |
| AU (1) | AU712404B2 (enExample) |
| BR (1) | BR9608265A (enExample) |
| CA (1) | CA2216099C (enExample) |
| CZ (1) | CZ293135B6 (enExample) |
| DE (1) | DE69633332T2 (enExample) |
| ES (1) | ES2227586T3 (enExample) |
| GE (1) | GEP20002297B (enExample) |
| HU (1) | HUP9801995A3 (enExample) |
| IL (1) | IL118075A0 (enExample) |
| MX (1) | MX9708582A (enExample) |
| NO (1) | NO310287B1 (enExample) |
| NZ (1) | NZ307089A (enExample) |
| PL (1) | PL323240A1 (enExample) |
| PT (1) | PT824524E (enExample) |
| RU (1) | RU2167155C2 (enExample) |
| SK (1) | SK150297A3 (enExample) |
| TW (1) | TW450962B (enExample) |
| UA (1) | UA56992C2 (enExample) |
| WO (1) | WO1996035678A1 (enExample) |
| ZA (1) | ZA963281B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1034167A1 (en) * | 1997-09-25 | 2000-09-13 | PHARMACIA & UPJOHN COMPANY | Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors |
| US6111111A (en) * | 1997-10-23 | 2000-08-29 | Kuraray Co., Ltd. | Intermediates for producing pyridine derivatives |
| EE200100155A (et) | 1998-09-17 | 2002-08-15 | Bristol-Myers Squibb Company | Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni |
| US7358254B2 (en) | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| WO2001000214A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
| RU2382648C2 (ru) * | 2004-12-03 | 2010-02-27 | Мерк Энд Ко., Инк. | Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения |
| DK1858861T3 (da) * | 2005-03-04 | 2010-11-08 | Tibotec Pharm Ltd | HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner |
| US7923056B2 (en) | 2007-06-01 | 2011-04-12 | Illinois Tool Works Inc. | Method and apparatus for dispensing material on a substrate |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| CN101638391B (zh) * | 2009-08-21 | 2011-04-27 | 山东大学 | 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用 |
| WO2011103559A1 (en) | 2010-02-22 | 2011-08-25 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CN103140474A (zh) * | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| KR101360587B1 (ko) * | 2012-11-01 | 2014-03-10 | 현대자동차주식회사 | 스마트 도어 언록 시스템 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| PH12022550783A1 (en) * | 2019-10-04 | 2023-07-31 | Enanta Pharm Inc | Antiviral heterocyclic compounds |
| CA3167672A1 (en) * | 2020-01-20 | 2021-07-29 | Agrematch Ltd. | Compositions for crop protection |
| AU2022326463A1 (en) | 2021-08-10 | 2024-02-22 | Novartis Pharma Ag | Compounds and compositions for treating conditions associated with sting activity |
| CN114057707A (zh) * | 2021-11-24 | 2022-02-18 | 上海应用技术大学 | 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法 |
| JP2025504415A (ja) * | 2022-01-12 | 2025-02-12 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2295560A (en) * | 1941-06-18 | 1942-09-15 | Gen Electric | Pyrimidine derivatives |
| GB744867A (en) * | 1952-10-29 | 1956-02-15 | American Cyanamid Co | Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof |
| US3940394A (en) * | 1972-03-31 | 1976-02-24 | Santilli Arthur A | 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides |
| US3940240A (en) * | 1974-07-11 | 1976-02-24 | Ina Seito Co., Ltd. | Baking method and kiln for tile |
| DE3369514D1 (en) * | 1983-05-05 | 1987-03-05 | Heumann Ludwig & Co Gmbh | Pyrimidinethioalkyl pyridine derivatives, process for their preparation and medicines containing these compounds |
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPS62209062A (ja) * | 1986-03-10 | 1987-09-14 | Yamanouchi Pharmaceut Co Ltd | ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物 |
| JPH07107056B2 (ja) * | 1987-01-30 | 1995-11-15 | 日清製粉株式会社 | ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤 |
| WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| HU203736B (en) * | 1989-04-06 | 1991-09-30 | Gyogyszerkutato Intezet | Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them |
| MX9203454A (es) * | 1989-12-28 | 1992-08-01 | Upjohn Co | Compuestos anti sida diaromaticos substituidos. |
| US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
| KR100236808B1 (ko) * | 1991-07-03 | 2000-02-01 | 로렌스 티. 마이젠헬더 | 에이즈 치료약제로서의 치환된 인돌 |
| GB2266716A (en) * | 1992-05-05 | 1993-11-10 | Merck & Co Inc | Inhibitors of HIV reverse transcriptase |
| JP3077046B2 (ja) * | 1992-08-31 | 2000-08-14 | 久光製薬株式会社 | 新規なキナゾリン誘導体 |
| EP0720607A1 (en) * | 1993-09-17 | 1996-07-10 | PHARMACIA & UPJOHN COMPANY | Substituted tetronic acids useful for treating hiv and other retroviruses |
| EP0728130A1 (en) * | 1993-11-12 | 1996-08-28 | PHARMACIA & UPJOHN COMPANY | Pyrimidine-thioalkyl and alkylether compounds |
| WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| PL318298A1 (en) * | 1994-07-20 | 1997-06-09 | Byk Gulden Lomberg Chem Fab | Thiopyridil compounds for fighting against heliobacter |
-
1996
- 1996-03-05 UA UA97125800A patent/UA56992C2/uk unknown
- 1996-04-24 ZA ZA9603281A patent/ZA963281B/xx unknown
- 1996-04-29 IL IL11807596A patent/IL118075A0/xx unknown
- 1996-05-03 MX MX9708582A patent/MX9708582A/es not_active IP Right Cessation
- 1996-05-03 PL PL96323240A patent/PL323240A1/xx unknown
- 1996-05-03 PT PT96913306T patent/PT824524E/pt unknown
- 1996-05-03 WO PCT/US1996/006119 patent/WO1996035678A1/en not_active Ceased
- 1996-05-03 JP JP8534120A patent/JPH11507017A/ja not_active Withdrawn
- 1996-05-03 NZ NZ307089A patent/NZ307089A/xx unknown
- 1996-05-03 US US08/945,153 patent/US6043248A/en not_active Expired - Fee Related
- 1996-05-03 AT AT96913306T patent/ATE275550T1/de not_active IP Right Cessation
- 1996-05-03 RU RU97120116/04A patent/RU2167155C2/ru not_active IP Right Cessation
- 1996-05-03 EP EP04010159A patent/EP1449835A3/en not_active Withdrawn
- 1996-05-03 GE GEAP19964013A patent/GEP20002297B/en unknown
- 1996-05-03 HU HU9801995A patent/HUP9801995A3/hu unknown
- 1996-05-03 SK SK1502-97A patent/SK150297A3/sk unknown
- 1996-05-03 KR KR1019970707927A patent/KR100445498B1/ko not_active Expired - Fee Related
- 1996-05-03 ES ES96913306T patent/ES2227586T3/es not_active Expired - Lifetime
- 1996-05-03 DE DE69633332T patent/DE69633332T2/de not_active Expired - Fee Related
- 1996-05-03 BR BR9608265A patent/BR9608265A/pt not_active Application Discontinuation
- 1996-05-03 CA CA002216099A patent/CA2216099C/en not_active Expired - Fee Related
- 1996-05-03 AU AU56353/96A patent/AU712404B2/en not_active Ceased
- 1996-05-03 EP EP96913306A patent/EP0824524B1/en not_active Expired - Lifetime
- 1996-05-03 CN CNB961937912A patent/CN1152022C/zh not_active Expired - Fee Related
- 1996-05-03 CN CNA200410032589XA patent/CN1535958A/zh active Pending
- 1996-05-03 CZ CZ19973491A patent/CZ293135B6/cs not_active IP Right Cessation
- 1996-05-07 TW TW085105432A patent/TW450962B/zh not_active IP Right Cessation
-
1997
- 1997-11-07 NO NO19975129A patent/NO310287B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA963281B (en) | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds. | |
| BR9815166A (pt) | "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral" | |
| NL300347I1 (nl) | Benzoxazinonen als remmers van hiv omgekeerde transcriptase | |
| BR0013771A (pt) | Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica | |
| MD1507F2 (en) | Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition | |
| ATE250063T1 (de) | Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen | |
| AP9701041A0 (en) | Pyridylpyrrole compounds. | |
| DE69019533D1 (de) | Behandlung von hiv-infizierungen und nützliche verbindungen dafür. | |
| WO1999019304A3 (en) | Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors | |
| ES2123156T3 (es) | Compuestos y procedimientos de inhibicion de hiv y virus semejantes. | |
| GB9313557D0 (en) | Pharmaceutical compositions | |
| MX9708452A (es) | Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma. | |
| ATE376445T1 (de) | Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge | |
| ZA991029B (en) | Composition and methods for treatment of hiv infections. | |
| EA200100494A1 (ru) | Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b | |
| IE893991L (en) | 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition | |
| MY121604A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt | |
| FR2700166B1 (fr) | Dérivés de pyrrolidine, leur préparation et les médicaments les contenant. | |
| KR950702838A (ko) | 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4) | |
| TR200103704T2 (tr) | Terapötik ajanlar | |
| SE9402241D0 (sv) | Inhibitor | |
| ES2107174T3 (es) | Derivados del etoposido, su procedimiento de preparacion, su utilizacion a titulo de medicamento y su utilizacion para la preparacion de un medicamento destinado al tratamiento anticanceroso. | |
| SE9603284D0 (sv) | New compounds | |
| EP0355409A3 (en) | Use of prolylendopeptidase inhibitors in the treatment of aids | |
| DK0457336T3 (da) | Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |